Trial Profile
A compassionate access program assessing the combination of Veyonda with 177Lu-PSMA therapy for patients with advanced, treatment resistant, metastatic prostate cancer (mCRPC) being treated with theranostics
Status:
Planning
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
- Indications Prostate cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Noxopharm
Most Recent Events
- 30 Jun 2022 Status changed from suspended to planning, According to a Novartis media release.
- 30 Jun 2022 According to Novartis media release, company has remediated the issues that led to the temporary, voluntary suspension. These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.Company restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan) in the US, in most countries globally.
- 05 May 2022 According to Novartis media release, Novartis is putting a temporary hold on screening and enrollment for 177Lu-PSMA-617 clinical trials globally, hence status changed to suspended.